Valeo Launches Onstryv (safinamide tablet) for the Treatment of Parkinson’s Disease in Canada

Shots:

• The launch of Onstryv follows its Health Canada approval received on Jan 15, 2019 as an add-on therapy to a levodopa regimen indicated to treat signs and symptoms of idiopathic Parkinson’s disease in patients with off episodes
• Valeo Pharma has exclusive rights for Onstryv and is responsible for all regulatory, quality, commercialization and distribution activities in Canada under an agreement with Zambon signed on Apr’2017
• Onstryv (marketed as Xadago in ROW) is an oral, selective & reversible MAO-B-inhibitor, available in Canadian pharmacies as 50mg & 100mg tablets

Click here to read full press release/ article | Ref: Business Wire | Image: LinkedIn